A new pair of clinical trials conducted at the Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center in Baltimore, indicate that two drugs, the immune checkpoint inhibitor Keytruda, along with the immune-boosting Yervoy, show promising signs for treating advanced melanoma. According to Dr. Suzanne Topalian, director of the Melanoma Program at Johns Hopkins, these drugs "prod the immune system to attack and destroy cancer cells."
Click here to read more about this trial, presented on April 20, 2015 at the annual meeting of the American Association for Cancer Research in Philadelphia.
No comments:
Post a Comment